A Phase 3 interventional study of Teriflunomide and Evobrutinib in Relapsing Multiple Sclerosis, sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany. Terminated at 279 sites in 31 countries. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2025-06-12.
Sponsored by Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany — none open to participants now, 1 under way, none of them phase 3. Multiple Sclerosis · Merck KGaA, Darmstadt, Germany.
Among the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany, this one is the 2nd largest by enrollment of the 33 interventional ones that give a count, is one of 2 that started in 2020, is one of 11 in phase 3, and was the 63rd registered.
3,271 studies on the registry are indexed under Multiple Sclerosis; 665 are open to participants now.
Browse Multiple Sclerosis studies →None of the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany is open now. The open studies under Multiple Sclerosis, anywhere →
Of the 433 Multiple Sclerosis studies recruiting now, 163 (38%) set no upper age limit and 214 (49%) stop at 75 or younger; 40 take children under 18; 96 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
71 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 2 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,124 is above the median of 50 across 2,207 interventional studies indexed under Multiple Sclerosis.
Median enrollment 219 across the 33 interventional studies, 253 across the 38 observational. Of the 70 that completed or were terminated, 42 (60%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, one of the names counted as Merck KGaA, Darmstadt, Germany. Under that name alone:
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany is the lead sponsor of 56 studies on the registry; 5 are open to participants now.
None of the studies under way reaches primary completion within a year.
Among the 71 studies in Multiple Sclerosis by Merck KGaA, Darmstadt, Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The study is to evaluate the efficacy and safety of evobrutinib administered orally twice daily versus Teriflunomide (Aubagio®), administered orally once daily in participants with Relapsing Multiple Sclerosis (RMS). Participants who complete the double-blind treatment period (DBTP) and double-blind extension period (DBEP) prior to approval of a separate long-term follow-up study in their country will get an option for evobrutinib treatment continuation through a 96-week open-label extension (OLE) period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants with secondary progressive MS without evidence of relapse
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Teriflunomide
Drug: Evobrutinib
Participants received Teriflunomide at a dose of 14 milligrams (mg) orally once daily up to 156 weeks in Double blind treatment period (DBTP) followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in double blind extension (DBE) period and followed by once daily oral doses of Teriflunomide 14 mg up to 96 weeks in open label extension (OLE) period.
Participants received Evobrutinib at a dose of 45 mg orally twice daily up to 156 weeks in Double blind treatment period (DBTP) followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in double blind extension (DBE) period and followed by twice daily oral doses of Evobrutinib 45 mg up to 96 weeks in open label extension (OLE) period.
Also known as: M2951
Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR)
The qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than \[\>\] 24 hours, no fever, infection, injury, adverse events (AEs,) and preceded by a stable or improving neurological state for more than or equal to \[\>=\] 30 days).
Time frame: From baseline to 172 weeks
Open Label Extension (OLE) Period: Number of Participants With Adverse Events (AEs) and Serious AEs
Adverse event (AE): Any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important.
Time frame: From OLE Baseline (DBTP Week 96) to OLE Week 52
DBTP and DBE Period: Percentage of Participants Without 12-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)
Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 12 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 12 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 12-week CDP.
Time frame: Week 96 and Week 156 (combined DBTP and DBE period)
DBTP and DBE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)
Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 24 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 24-week CDP.
Time frame: Week 96 and Week 156 (combined DBTP and DBE periods)
DBTP and DBE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)
Disability improvement was defined as a reduction of 1 point from Baseline EDSS score when the Baseline score is \>= 2 and less than or equal to \[\<=\] 6 and a reduction of 0.5 point from Baseline EDSS score when the Baseline score is \>= 6.5 and \<= 9.5. Disability improvement is considered sustained when the initial reduction in the EDSS score is confirmed at a regularly scheduled visit at least 24 weeks after the initial reduction. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants with 12-week CDI.
Time frame: Week 96 and Week 156 (combined DBTP and DBE periods)
DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Physical Function (PF) Score at Week 48, Week 96, Week 120, Week 144 and Week 156
Physical function was assessed with PROMISnq Short Form v2.0 - Physical Function - Multiple Sclerosis 15a (PROMISnq PF(MS) 15a). PROMISnq PF(MS) 15a assesses a participant's abilities and limitations with respect to everyday physical activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 10 to 65. Higher T-scores represent higher physical function. Change from baseline in PROMIS PF score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).
Time frame: Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 (combined DBTP and DBE periods)
DBTP and DBE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Score at Week 48, Week 96, Week 120, Week 144 and Week 156
PROMIS Fatigue score was assessed with PROMIS Short Form v1.0 - Fatigue - Multiple Sclerosis 8a (PROMIS Fatigue (MS) 8a). PROMIS Fatigue (MS) 8a assesses level of fatigue and its interference on daily activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 33 to 85. Higher T-scores represent higher fatigue. Change from baseline in PROMIS fatigue score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).
Time frame: Baseline, Week 48, Week 96, Week 120, Week 144 and Week 156 (combined DBTP and DBE periods)
DBTP and DBE Period: Total Number of T1 Gadolinium-positive (Gd+) Lesions
Analysis of Gadolinium-positive T1 lesions was done using magnetic resonance imaging (MRI) scans.
Time frame: From baseline to 176 weeks
DBTP and DBE Period: New or Enlarging T2 Lesions Rate
Analysis of new or enlarging T2 lesions rate was done using magnetic resonance imaging (MRI) scans. Negative binomial model for lesion count (summed over scans) includes treatment and covariates based on randomization strata and baseline volume of T2 lesion (continuous), with offset equal to the log of the time in years between the last available MRI scan and the baseline scan.
Time frame: From baseline to 176 weeks
DBTP Period: Neurofilament Light Chain Concentration (NfL) at Week 12
NfL is a biomarker of neuro-axonal damage whose concentration was assessed in blood at Week 12.
Time frame: Week 12
DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Adverse Events of Special Interest (AESIs)
Adverse event (AE): Any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: those AEs with an onset date on or after the date of first study intervention administration, or AEs present prior to any study intervention administration but exacerbating after. TEAEs included both Serious TEAEs and non-serious TEAEs. AESIs included liver AEs (possible drug-induced, non-infectious, non-alcoholic, and immune-mediated), infections (serious and opportunistic infections), lipase and amylase elevation, and seizure.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) by Severity
Severity of adverse events (AE) were assessed by the investigator per the National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with Grades 1, 2, 3, 4 and 5 were reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Vital Signs: Diastolic Blood Pressure and Systolic Blood Pressure
Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: diastolic blood pressure and systolic blood pressure from baseline up to 176 weeks were reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Vital Signs: Pulse Rate
Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: pulse rate from baseline up to baseline up to 176 weeks was reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Vital Signs: Respiratory Rate
Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: respiratory rate from baseline up to 176 weeks was reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Vital Signs: Weight
Changes in vital signs: weight from baseline up to 176 weeks was reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Vital Signs: Temperature
Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: Temperature from baseline up to 176 weeks was reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate
Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in ECG parameter: heart rate from baseline up to 176 weeks was reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs) Parameters: QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration
QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in ECG parameter: QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration from baseline up to 176 weeks were reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hemoglobin and Erythrocytes Mean Corpuscular Hemoglobin (HGB) Concentration
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin. Changes in hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin from baseline up to 176 weeks were reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes. Changes in hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes from baseline up to 176 weeks were reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hematocrit
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Hematocrit. Changes in hematology parameter: Hematocrit from baseline up to 176 weeks was reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Changes in hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin from baseline up to 176 weeks was reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Changes in hematology parameter: Erythrocytes Mean Corpuscular Volume from baseline up to 176 weeks was reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Bilirubin and Creatinine
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Bilirubin and Creatinine. Changes in biochemistry parameters: Bilirubin and Creatinine from baseline up to 176 weeks were reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase. Changes in biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase from baseline up to 176 weeks were reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium. Changes in biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium from baseline up to 176 weeks were reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameters: Total Protein and Albumin
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Total Protein and Albumin. Changes in biochemistry parameters: Total Protein and Albumin from baseline up to 176 weeks were reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Biochemistry Parameter: Glomerular Filtration Rate
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameter: Glomerular Filtration Rate. Changes in biochemistry parameter: Glomerular Filtration Rate from baseline up to 176 weeks was reported. The Glomerular Filtration Rate will be measured as milliliter per minute per 1.73 square meter (mL/min/1.73m\^2).
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Potential of Hydrogen (pH) of Urine
Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: pH. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Changes in urinalyses parameter: pH from baseline up to 176 weeks was reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Specific Gravity of Urine
Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: Specific Gravity of Urine. Changes in urinalyses parameter: Specific Gravity of Urine from baseline up to 176 weeks was reported.
Time frame: From baseline to 176 weeks
DBTP and DBE Periods: Absolute Concentrations of Immunoglobulin (Ig) Levels
Absolute Concentrations serum levels of IgG, IgA, IgM were assessed.
Time frame: At Week 176
DBTP and DBE Periods: Change From Baseline in Immunoglobulin (Ig) Levels
Change from baseline serum levels of IgG, IgA, IgM were assessed.
Time frame: Baseline to 176 weeks
OLE Period: Annualized Relapse Rate (ARR)
The qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than \[\>\] 24 hours, no fever, infection, injury, AEs, and preceded by a stable or improving neurological state for more than or equal to \[\>=\] 30 days).
Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52
OLE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS)
Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 24 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis).
Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52
OLE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS)
Disability improvement was defined as a reduction of 1 point from Baseline EDSS score when the Baseline score is \>= 2 and less than or equal to \[\<=\] 6 and a reduction of 0.5 point from Baseline EDSS score when the Baseline score is \>= 6.5 and \<= 9.5. Disability improvement is considered sustained when the initial reduction in the EDSS score is confirmed at a regularly scheduled visit at least 24 weeks after the initial reduction. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis).
Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52
OLE Period: Symbol Digit Modalities Test (SDMT)
The SDMT is a test of information processing speed. It consists of 9 abstract symbols. Each symbol is paired with a single digit. The participant is provided with a "key", showing each symbol digit pair. In addition, the participants are shown several rows of the 9 symbols, which are arranged pseudo-randomly, without the digit. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 seconds. The SDMT score ranges from 0 to 110 where higher scores indicated improvement and lower scores indicated worsening. Participant wise data was reported for this outcome measure.
Time frame: Assessed from OLE baseline to OLE Week 96; OLE Week 48 were reported for Participants 1 and 2 and OLE Week 12 were reported for Participant 3
OLE Period: Change From Baseline in PROMISnq Physical Function (PF) Multiple Sclerosis (MS) 15a at Week 52
Physical function was assessed with PROMISnq Short Form v2.0 - Physical Function - Multiple Sclerosis 15a (PROMISnq PF(MS) 15a). PROMISnq PF(MS) 15a assesses a participant's abilities and limitations with respect to everyday physical activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and ranges from 10 to 65. Higher T-scores represent higher physical function. Participant wise data was reported for this outcome measure.
Time frame: OLE Baseline (DBTP Week 96), OLE Week 52
OLE Period: Change From Baseline in Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue (MS) 8a Score at Week 52
PROMIS Fatigue score was assessed with PROMIS Short Form v1.0 - Fatigue - Multiple Sclerosis 8a (PROMIS Fatigue (MS) 8a). PROMIS Fatigue (MS) 8a assesses level of fatigue and its interference on daily activities. Results are reported as a T-score. In general, T-scores have a mean of 50, standard deviation of 10, and range from 33 to 85. Higher T-scores represent higher fatigue. Participant wise data was reported for this outcome measure.
Time frame: OLE baseline (DBTP Week 96), OLE Week 52
OLE Period: Number of Participants With Abnormalities in Laboratory Parameters
Laboratory investigation included hematology, biochemistry and coagulation. The number of participants with abnormalities in laboratory parameters were reported.
Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52
OLE Period: Number of Participants With Abnormalities in Vital Signs
Vital signs included temperature, pulse rate, respiration rate and blood pressure and weight (taken after 5 minutes in the sitting position). The number of participants with abnormalities in vital signs were reported.
Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52
OLE Period: Number of Participants With Abnormalities in Electrocardiograms (ECGs) Findings
ECG recordings included, heart rate, PR interval and QRS duration. ECG recordings were obtained after the participants have rested for at least 5 minutes in supine position. The number of participants with abnormalities in ECG findings were reported.
Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52
OLE Period: Number of New or Enlarging T2 Lesions
Analysis of number of new or enlarging T2 lesions was done using magnetic resonance imaging (MRI) scans. Negative binomial model for lesion count (summed over scans) includes treatment and covariates based on randomization strata and baseline volume of T2 lesion (continuous), with offset equal to the log of the time in years between the last available MRI scan and the baseline scan. Participant wise data was reported for this outcome measure.
Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52
OLE Period: Change From Baseline in T2 Lesion Volume
Change from baseline in T2 lesion volume was reported. Participant wise data was reported for this outcome measure.
Time frame: From OLE baseline (DBTP Week 96) to OLE Week 52
| Milestone | Teriflunomide | Evobrutinib |
|---|---|---|
| Started | 564 | 560 |
| Completed | 396 | 384 |
| Not completed | 168 | 176 |
| Withdrew: Adverse event | 56 | 72 |
| Withdrew: Lost to follow-up | 6 | 5 |
| Withdrew: Lack of efficacy | 19 | 23 |
| Withdrew: Withdrawal by subject | 56 | 55 |
| Withdrew: Death | 1 | 1 |
| Withdrew: Protocol non-compliance | 5 | 5 |
| Withdrew: Other reason | 24 | 14 |
| Withdrew: Randomized, but not treated | 1 | 1 |
| Milestone | Teriflunomide | Evobrutinib |
|---|---|---|
| Started | 377 | 359 |
| Completed | 371 | 346 |
| Not completed | 6 | 13 |
| Withdrew: Lack of efficacy | 1 | 2 |
| Withdrew: Withdrawal by subject | 0 | 1 |
| Withdrew: Adverse event | 2 | 0 |
| Withdrew: Lost to follow-up | 0 | 1 |
| Withdrew: Other reason | 3 | 9 |
| Milestone | Teriflunomide | Evobrutinib |
|---|---|---|
| Started | 0 | 3 |
| Completed | 0 | 0 |
| Not completed | 0 | 3 |
| Withdrew: Study termination | 0 | 3 |
The qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than \[\>\] 24 hours, no fever, infection, injury, adverse events (AEs,) and preceded by a stable or improving neurological state for more than or equal to \[\>=\] 30 days).
| relapses per year | Teriflunomide | Evobrutinib |
|---|---|---|
| Double Blind Treatment Period (DBTP) and Double Blind Extension (DBE) Period: Annualized Relapse Rate (ARR) | 0.13 (0.11 to 0.15) | 0.14 (0.12 to 0.16) |
Adverse event (AE): Any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. Therefore, an AE can be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of study drug, whether or not considered related to the study drug or worsening of pre-existing medical condition, whether or not related to study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important.
| Participants | Evobrutinib |
|---|---|
| Participants with AEs | 1 |
| Participants with Serious AEs | 0 |
Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 12 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 12 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 12-week CDP.
| percentage of participants | Teriflunomide | Evobrutinib |
|---|---|---|
| Week 96 | 91.0 (88.0 to 93.3) | 91.3 (88.3 to 93.5) |
| Week 156 | 86.0 (81.5 to 89.5) | 87.9 (83.5 to 91.1) |
Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 24 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants without 24-week CDP.
| percentage of participants | Teriflunomide | Evobrutinib |
|---|---|---|
| Week 96 | 94.3 (91.9 to 96.1) | 92.7 (89.9 to 94.7) |
| Week 156 | 92.3 (89.2 to 94.5) | 92.1 (89.2 to 94.3) |
Disability improvement was defined as a reduction of 1 point from Baseline EDSS score when the Baseline score is \>= 2 and less than or equal to \[\<=\] 6 and a reduction of 0.5 point from Baseline EDSS score when the Baseline score is \>= 6.5 and \<= 9.5. Disability improvement is considered sustained when the initial reduction in the EDSS score is confirmed at a regularly scheduled visit at least 24 weeks after the initial reduction. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis). Kaplan-Meier method was used to estimate the percentage of participants with 12-week CDI.
| percentage of participants | Teriflunomide | Evobrutinib |
|---|---|---|
| Week 96 | 7.9 (5.6 to 11.2) | 9.4 (6.7 to 13.0) |
| Week 156 | 8.8 (6.2 to 12.4) | 10.1 (7.3 to 13.9) |
Physical function was assessed with PROMISnq Short Form v2.0 - Physical Function - Multiple Sclerosis 15a (PROMISnq PF(MS) 15a). PROMISnq PF(MS) 15a assesses a participant's abilities and limitations with respect to everyday physical activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 10 to 65. Higher T-scores represent higher physical function. Change from baseline in PROMIS PF score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).
| units on a scale | Teriflunomide | Evobrutinib |
|---|---|---|
| Week 48 | -0.30 (-0.79 to 0.19) | 0.05 (-0.45 to 0.55) |
| Week 96 | -0.76 (-1.35 to -0.16) | -0.14 (-0.74 to 0.46) |
| Week 120 | -0.29 (-0.95 to 0.37) | -0.25 (-0.92 to 0.42) |
| Week 144 | -1.04 (-1.82 to -0.25) | -0.70 (-1.53 to 0.14) |
| Week 156 | -1.61 (-2.70 to -0.51) | -1.44 (-2.66 to -0.23) |
PROMIS Fatigue score was assessed with PROMIS Short Form v1.0 - Fatigue - Multiple Sclerosis 8a (PROMIS Fatigue (MS) 8a). PROMIS Fatigue (MS) 8a assesses level of fatigue and its interference on daily activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and range from 33 to 85. Higher T-scores represent higher fatigue. Change from baseline in PROMIS fatigue score was analyzed using Mixed Effect Model for Repeated Measures (MMRM) to evaluate the result of the 2 periods (DBTP and DBE).
| units on a scale | Teriflunomide | Evobrutinib |
|---|---|---|
| Week 48 | -1.39 (-1.98 to -0.81) | -1.82 (-2.41 to -1.23) |
| Week 96 | -1.60 (-2.32 to -0.87) | -2.14 (-2.88 to -1.41) |
| Week 120 | -1.44 (-2.25 to -0.63) | -1.32 (-2.15 to -0.50) |
| Week 144 | -1.88 (-2.90 to -0.86) | -0.98 (-2.06 to 0.10) |
| Week 156 | 0.72 (-0.78 to 2.22) | -0.21 (-1.90 to 1.48) |
Analysis of Gadolinium-positive T1 lesions was done using magnetic resonance imaging (MRI) scans.
| lesions per scan | Teriflunomide | Evobrutinib |
|---|---|---|
| DBTP and DBE Period: Total Number of T1 Gadolinium-positive (Gd+) Lesions | 0.35 (0.29 to 0.42) | 0.52 (0.43 to 0.62) |
Analysis of new or enlarging T2 lesions rate was done using magnetic resonance imaging (MRI) scans. Negative binomial model for lesion count (summed over scans) includes treatment and covariates based on randomization strata and baseline volume of T2 lesion (continuous), with offset equal to the log of the time in years between the last available MRI scan and the baseline scan.
| lesions per year | Teriflunomide | Evobrutinib |
|---|---|---|
| DBTP and DBE Period: New or Enlarging T2 Lesions Rate | 5.78 (5.02 to 6.65) | 5.45 (4.73 to 6.28) |
NfL is a biomarker of neuro-axonal damage whose concentration was assessed in blood at Week 12.
| nanogram per liter (ng/L) | Teriflunomide | Evobrutinib |
|---|---|---|
| DBTP Period: Neurofilament Light Chain Concentration (NfL) at Week 12 | 12.90 (12.48 to 13.34) | 12.88 (12.46 to 13.31) |
Adverse event (AE): Any untoward medical occurrence in a participant which does not necessarily have a causal relationship with the study drug. Serious AE: an AE that resulted in any of the following outcomes: death; life threatening; persistent/significant disability/incapacity; initial or prolonged inpatient hospitalization; congenital anomaly/birth defect or was otherwise considered medically important. TEAEs: those AEs with an onset date on or after the date of first study intervention administration, or AEs present prior to any study intervention administration but exacerbating after. TEAEs included both Serious TEAEs and non-serious TEAEs. AESIs included liver AEs (possible drug-induced, non-infectious, non-alcoholic, and immune-mediated), infections (serious and opportunistic infections), lipase and amylase elevation, and seizure.
| Participants | Teriflunomide | Evobrutinib |
|---|---|---|
| Participants with TEAEs | 485 | 482 |
| Participants with AESIs | 120 | 117 |
Severity of adverse events (AE) were assessed by the investigator per the National Cancer Institute- Common Terminology Criteria for Adverse Events (NCI-CTCAE), version 5.0. Grade 1 = Mild, Grade 2 = Moderate, Grade 3 = Severe, Grade 4 = Life-threatening and Grade 5 = Death. Number of participants with Grades 1, 2, 3, 4 and 5 were reported.
| Participants | Teriflunomide | Evobrutinib |
|---|---|---|
| Participants with Grade 1 | 50 | 56 |
| Participants with Grade 2 | 349 | 327 |
| Participants with Grade 3 | 82 | 88 |
| Participants with Grade 4 | 3 | 10 |
| Participants with Grade 5 | 1 | 1 |
Diastolic blood pressure and systolic blood pressure were measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: diastolic blood pressure and systolic blood pressure from baseline up to 176 weeks were reported.
| millimeter of mercury (mmHg) | Teriflunomide | Evobrutinib |
|---|---|---|
| Systolic Blood Pressure | 2.6 ± 11.18 | 0.2 ± 10.83 |
| Diastolic Blood Pressure | 1.8 ± 8.35 | 0.0 ± 8.67 |
Pulse rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: pulse rate from baseline up to baseline up to 176 weeks was reported.
| beats per minute | Teriflunomide | Evobrutinib |
|---|---|---|
| DBTP and DBE Periods: Change From Baseline in Vital Signs: Pulse Rate | 2.6 ± 10.22 | 1.9 ± 9.68 |
Respiratory rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: respiratory rate from baseline up to 176 weeks was reported.
| breaths per minute | Teriflunomide | Evobrutinib |
|---|---|---|
| DBTP and DBE Periods: Change From Baseline in Vital Signs: Respiratory Rate | -0.1 ± 1.76 | -0.2 ± 1.88 |
Changes in vital signs: weight from baseline up to 176 weeks was reported.
| kilograms (kg) | Teriflunomide | Evobrutinib |
|---|---|---|
| DBTP and DBE Periods: Change From Baseline in Vital Signs: Weight | -0.21 ± 5.867 | 0.48 ± 5.490 |
Temperature was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in vital signs: Temperature from baseline up to 176 weeks was reported.
| degree Celsius | Teriflunomide | Evobrutinib |
|---|---|---|
| DBTP and DBE Periods: Change From Baseline in Vital Signs: Temperature | 0.00 ± 0.326 | 0.02 ± 0.319 |
Heart rate was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in ECG parameter: heart rate from baseline up to 176 weeks was reported.
| beats per minute | Teriflunomide | Evobrutinib |
|---|---|---|
| DBTP and DBE Periods: Change From Baseline in Electrocardiograms (ECGs) Parameter: Heart Rate | 3.0 ± 10.90 | -0.1 ± 12.55 |
QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration was measured after at least 5 minutes of rest for the participant in a quiet sitting without distractions. Changes in ECG parameter: QT Interval - Fridericia's Correction Formula, PR Interval and QRS Duration from baseline up to 176 weeks were reported.
| milliseconds (msec) | Teriflunomide | Evobrutinib |
|---|---|---|
| QT Interval - Fridericia's Correction Formula | -2.77 ± 16.005 | -1.37 ± 12.053 |
| PR Interval | -5.2 ± 14.31 | -2.5 ± 14.65 |
| QRS Duration | -3.7 ± 7.48 | -1.5 ± 10.82 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin. Changes in hematology parameters: erythrocytes mean corpuscular HGB concentration and hemoglobin from baseline up to 176 weeks were reported.
| gram per liter (g/L) | Teriflunomide | Evobrutinib |
|---|---|---|
| Hemoglobin | -3.5 ± 10.74 | -2.8 ± 11.34 |
| Erythrocytes Mean Corpuscular HGB Concentration | -2.7 ± 12.43 | -1.0 ± 11.96 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes. Changes in hematology parameters: Platelets, Leukocytes, Neutrophils, Eosinophils, Basophils, Monocytes, Lymphocytes and Reticulocytes from baseline up to 176 weeks were reported.
| 10^9 cells per liter | Teriflunomide | Evobrutinib |
|---|---|---|
| Platelets | -4.8 ± 47.09 | 8.8 ± 53.83 |
| Leukocytes | -0.17 ± 2.165 | -0.09 ± 1.958 |
| Neutrophils | -0.316 ± 1.8846 | -0.210 ± 1.8356 |
| Eosinophils | 0.0510 ± 0.15999 | 0.0203 ± 0.15853 |
| Basophils | -0.0009 ± 0.03657 | -0.0003 ± 0.03786 |
| Monocytes | 0.0785 ± 0.18171 | 0.0656 ± 0.17816 |
| Lymphocytes | -0.0307 ± 0.58566 | -0.0401 ± 0.58108 |
| Reticulocytes | 0.488 ± 20.2014 | -0.827 ± 17.6824 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Hematocrit. Changes in hematology parameter: Hematocrit from baseline up to 176 weeks was reported.
| percentage of cells | Teriflunomide | Evobrutinib |
|---|---|---|
| DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Hematocrit | -0.0069 ± 0.03359 | -0.0076 ± 0.03238 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin. Changes in hematology parameter: Erythrocytes Mean Corpuscular Hemoglobin from baseline up to 176 weeks was reported.
| picogram (pg) | Teriflunomide | Evobrutinib |
|---|---|---|
| DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin | -0.61 ± 1.588 | -0.62 ± 1.956 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the hematology parameter: Erythrocytes Mean Corpuscular Volume. Changes in hematology parameter: Erythrocytes Mean Corpuscular Volume from baseline up to 176 weeks was reported.
| femtoliters | Teriflunomide | Evobrutinib |
|---|---|---|
| DBTP and DBE Periods: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume | -1.42 ± 5.999 | -1.75 ± 4.895 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Bilirubin and Creatinine. Changes in biochemistry parameters: Bilirubin and Creatinine from baseline up to 176 weeks were reported.
| micromoles per liter (mcmol/L) | Teriflunomide | Evobrutinib |
|---|---|---|
| Bilirubin | -0.08 ± 4.792 | 0.15 ± 4.792 |
| Creatinine | 0.6 ± 12.76 | 2.4 ± 8.67 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase. Changes in biochemistry parameters: Aspartate Aminotransferase, Alanine Aminotransferase, Alkaline Phosphatase, Amylase, Lipase, Gamma Glutamyl Transferase and Lactate Dehydrogenase from baseline up to 176 weeks were reported.
| units per liter (U/L) | Teriflunomide | Evobrutinib |
|---|---|---|
| Aspartate Aminotransferase | 2.32 ± 18.190 | 6.49 ± 64.249 |
| Alanine Aminotransferase | 4.06 ± 23.308 | 8.55 ± 52.866 |
| Alkaline Phosphatase | 4.20 ± 23.289 | 7.65 ± 20.252 |
| Amylase | -0.5 ± 17.04 | 2.8 ± 16.84 |
| Lipase | -2.5 ± 33.36 | 3.5 ± 17.33 |
| Gamma Glutamyl Transferase | 4.28 ± 21.091 | 5.51 ± 40.098 |
| Lactate Dehydrogenase | 6.16 ± 28.235 | -4.53 ± 26.014 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium. Changes in biochemistry parameters: Sodium, Potassium, Calcium, Magnesium, Glucose, Chloride, Urea Nitrogen, Phosphate, Bicarbonate and Corrected Calcium from baseline up to 176 weeks were reported.
| millimole per liter (mmol/L) | Teriflunomide | Evobrutinib |
|---|---|---|
| Sodium | 0.9128 ± 2.34334 | 0.7904 ± 2.28990 |
| Potassium | 0.0320 ± 0.43741 | 0.0893 ± 0.42341 |
| Calcium | 0.004 ± 0.1139 | -0.002 ± 0.1029 |
| Magnesium | 0.004 ± 0.0682 | 0.002 ± 0.0656 |
| Glucose | 0.06 ± 0.928 | 0.25 ± 1.146 |
| Chloride | 1.8 ± 3.42 | 1.7 ± 2.95 |
| Urea Nitrogen | 0.222 ± 1.2668 | 0.114 ± 1.2654 |
| Phosphate | -0.053 ± 0.2048 | -0.026 ± 0.1724 |
| Bicarbonate | 0.05 ± 2.561 | 0.04 ± 2.725 |
| Corrected Calcium | 0.0297 ± 0.09428 | 0.0317 ± 0.09071 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameters: Total Protein and Albumin. Changes in biochemistry parameters: Total Protein and Albumin from baseline up to 176 weeks were reported.
| gram per liter (g/L) | Teriflunomide | Evobrutinib |
|---|---|---|
| Total protein | -1.26 ± 4.865 | -0.47 ± 4.417 |
| Albumin | -1.28 ± 3.520 | -1.67 ± 3.284 |
Blood samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the biochemistry parameter: Glomerular Filtration Rate. Changes in biochemistry parameter: Glomerular Filtration Rate from baseline up to 176 weeks was reported. The Glomerular Filtration Rate will be measured as milliliter per minute per 1.73 square meter (mL/min/1.73m\^2).
| mL/min/1.73m^2 | Teriflunomide | Evobrutinib |
|---|---|---|
| DBTP and DBE Periods: Change From Baseline in Biochemistry Parameter: Glomerular Filtration Rate | -3.3 ± 13.82 | -5.6 ± 13.54 |
Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: pH. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. A pH of 7 is neutral. A pH less than 7 is acidic, and a pH greater than 7 is basic. Normal urine has a slightly acid pH (5.0 - 6.0). Changes in urinalyses parameter: pH from baseline up to 176 weeks was reported.
| pH | Teriflunomide | Evobrutinib |
|---|---|---|
| DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Potential of Hydrogen (pH) of Urine | -0.08 ± 0.886 | 0.01 ± 0.913 |
Urine samples were collected in a fasted condition (after a fast of at least 12 hours) to analyze the urinalyses parameter: Specific Gravity of Urine. Changes in urinalyses parameter: Specific Gravity of Urine from baseline up to 176 weeks was reported.
| Kilogram per cubic meter | Teriflunomide | Evobrutinib |
|---|---|---|
| DBTP and DBE Periods: Change From Baseline in Urinalyses Parameter: Specific Gravity of Urine | 0.0006 ± 0.03891 | 0.0011 ± 0.02189 |
Absolute Concentrations serum levels of IgG, IgA, IgM were assessed.
| gram per liter (g/L) | Teriflunomide | Evobrutinib |
|---|---|---|
| IgA | 1.750 ± 0.7987 | 2.503 ± 1.0582 |
| IgG | 9.693 ± 2.1096 | 10.529 ± 2.2363 |
| IgM | 1.101 ± 0.6096 | 1.181 ± 0.6619 |
Change from baseline serum levels of IgG, IgA, IgM were assessed.
| gram per liter (g/L) | Teriflunomide | Evobrutinib |
|---|---|---|
| IgA | -0.262 ± 0.3572 | 0.483 ± 0.5320 |
| IgG | -0.733 ± 1.4414 | 0.105 ± 1.4556 |
| IgM | -0.165 ± 0.2979 | -0.187 ± 0.2794 |
The qualifying relapse is the occurrence of new or worsening neurological symptoms attributable to Multiple Sclerosis (MS) (for more than \[\>\] 24 hours, no fever, infection, injury, AEs, and preceded by a stable or improving neurological state for more than or equal to \[\>=\] 30 days).
| relapses per year | Evobrutinib |
|---|---|
| OLE Period: Annualized Relapse Rate (ARR) | NA (NA to NA) |
Disability progression was defined as increase in EDSS of greater than or equal to \[\>=\] 1 point from baseline EDSS score, if EDSS score at baseline is 5.0 or less and an increase of \>=0.5 point, if the baseline score is 5.5. Disability progression is considered sustained for 24 weeks when the initial increase in the EDSS is confirmed at a regularly scheduled visit at least 24 weeks after the initial documentation of neurological worsening. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis).
| percentage of participants | Evobrutinib |
|---|---|
| OLE Period: Percentage of Participants Without 24-Week Confirmed Disability Progression (CDP) as Measured by Expanded Disability Status Scale (EDSS) | 0 |
Disability improvement was defined as a reduction of 1 point from Baseline EDSS score when the Baseline score is \>= 2 and less than or equal to \[\<=\] 6 and a reduction of 0.5 point from Baseline EDSS score when the Baseline score is \>= 6.5 and \<= 9.5. Disability improvement is considered sustained when the initial reduction in the EDSS score is confirmed at a regularly scheduled visit at least 24 weeks after the initial reduction. The total EDSS score ranges from 0 (normal) to 10 (death due to multiple sclerosis).
| percentage of participants | Evobrutinib |
|---|---|
| OLE Period: Percentage of Participants With 24-Week Confirmed Disability Improvement (CDI) as Measured by Expanded Disability Status Scale (EDSS) | 0 |
The SDMT is a test of information processing speed. It consists of 9 abstract symbols. Each symbol is paired with a single digit. The participant is provided with a "key", showing each symbol digit pair. In addition, the participants are shown several rows of the 9 symbols, which are arranged pseudo-randomly, without the digit. Participants are asked to voice the digit associated with each symbol as rapidly as possible for 90 seconds. The SDMT score ranges from 0 to 110 where higher scores indicated improvement and lower scores indicated worsening. Participant wise data was reported for this outcome measure.
| units on a scale | Evobrutinib |
|---|---|
| Participant 1 | 60 |
| Participant 2 | 40 |
| Participant 3 | 50 |
Physical function was assessed with PROMISnq Short Form v2.0 - Physical Function - Multiple Sclerosis 15a (PROMISnq PF(MS) 15a). PROMISnq PF(MS) 15a assesses a participant's abilities and limitations with respect to everyday physical activities. Results are reported as a T-score. In the general population, T-scores have a mean of 50, standard deviation of 10, and ranges from 10 to 65. Higher T-scores represent higher physical function. Participant wise data was reported for this outcome measure.
| T-score | Evobrutinib |
|---|---|
| Participant 1 | 52 |
| Participant 2 | 63 |
| Participant 3 | 51 |
PROMIS Fatigue score was assessed with PROMIS Short Form v1.0 - Fatigue - Multiple Sclerosis 8a (PROMIS Fatigue (MS) 8a). PROMIS Fatigue (MS) 8a assesses level of fatigue and its interference on daily activities. Results are reported as a T-score. In general, T-scores have a mean of 50, standard deviation of 10, and range from 33 to 85. Higher T-scores represent higher fatigue. Participant wise data was reported for this outcome measure.
| T-score | Evobrutinib |
|---|---|
| Participant 1 | 43 |
| Participant 2 | 42 |
| Participant 3 | 41 |
Laboratory investigation included hematology, biochemistry and coagulation. The number of participants with abnormalities in laboratory parameters were reported.
| Participants | Evobrutinib |
|---|---|
| Hematology | 1 |
| Biochemistry | 1 |
| Coagulation | 0 |
Vital signs included temperature, pulse rate, respiration rate and blood pressure and weight (taken after 5 minutes in the sitting position). The number of participants with abnormalities in vital signs were reported.
| Participants | Evobrutinib |
|---|---|
| OLE Period: Number of Participants With Abnormalities in Vital Signs | 0 |
ECG recordings included, heart rate, PR interval and QRS duration. ECG recordings were obtained after the participants have rested for at least 5 minutes in supine position. The number of participants with abnormalities in ECG findings were reported.
| Participants | Evobrutinib |
|---|---|
| OLE Period: Number of Participants With Abnormalities in Electrocardiograms (ECGs) Findings | 1 |
Analysis of number of new or enlarging T2 lesions was done using magnetic resonance imaging (MRI) scans. Negative binomial model for lesion count (summed over scans) includes treatment and covariates based on randomization strata and baseline volume of T2 lesion (continuous), with offset equal to the log of the time in years between the last available MRI scan and the baseline scan. Participant wise data was reported for this outcome measure.
| number of lesions | Evobrutinib |
|---|---|
| Participant 1 | 11 |
| Participant 2 | 0 |
| Participant 3 | 0 |
Change from baseline in T2 lesion volume was reported. Participant wise data was reported for this outcome measure.
| milliliter (mL) | Evobrutinib |
|---|---|
| Participant 1 | 0.471 |
| Participant 2 | -0.111 |
| Participant 3 | 0 |
Collected over From baseline to 176 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Teriflunomide | 1/563 (0.2%) | 33/563 (5.9%) | 409/563 (72.6%) |
| Evobrutinib | 1/559 (0.2%) | 45/559 (8.1%) | 361/559 (64.6%) |
| Event | Teriflunomide | Evobrutinib |
|---|---|---|
| Multiple sclerosis relapseNervous system disorders | 3/563 | 4/559 |
| COVID-19 pneumoniaInfections and infestations | 4/563 | 3/559 |
| COVID-19Infections and infestations | 0/563 | 3/559 |
| Femoral neck fractureInjury, poisoning and procedural complications | 0/563 | 2/559 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/563 | 2/559 |
| Abnormal uterine bleedingReproductive system and breast disorders | 0/563 | 2/559 |
| CellulitisInfections and infestations | 2/563 | 1/559 |
| PneumoniaInfections and infestations | 2/563 | 1/559 |
| Iron deficiency anaemiaBlood and lymphatic system disorders | 0/563 | 1/559 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/563 | 1/559 |
| Event | Teriflunomide | Evobrutinib |
|---|---|---|
| COVID-19Infections and infestations | 108/563 | 121/559 |
| Alanine aminotransferase increasedInvestigations | 86/563 | 77/559 |
| HeadacheNervous system disorders | 75/563 | 81/559 |
| NasopharyngitisInfections and infestations | 61/563 | 67/559 |
| AlopeciaSkin and subcutaneous tissue disorders | 59/563 | 32/559 |
| Aspartate aminotransferase increasedInvestigations | 54/563 | 51/559 |
| DiarrhoeaGastrointestinal disorders | 53/563 | 15/559 |
| Neutrophil count decreasedInvestigations | 50/563 | 25/559 |
| Upper respiratory tract infectionInfections and infestations | 42/563 | 36/559 |
| NeutropeniaBlood and lymphatic system disorders | 41/563 | 20/559 |
Full Analysis Set (FAS) included all participants who were randomized to study treatment.
| Age, Continuous(Years) | Teriflunomide | Evobrutinib | Total |
|---|---|---|---|
| Mean | 38 ± 9.5 | 37 ± 9.6 | 38 ± 9.5 |
| Sex: Female, Male(Participants) | Teriflunomide | Evobrutinib | Total |
|---|---|---|---|
| Female | 374 | 377 | 751 |
| Male | 190 | 183 | 373 |
| Race/Ethnicity, Customized(Participants) | Teriflunomide | Evobrutinib | Total |
|---|---|---|---|
| Ethnicity-Hispanic or Latino | 60 | 63 | 123 |
| Ethnicity-Not Hispanic or Latino | 504 | 497 | 1001 |
| Race-American Indian or Alaska Native | 6 | 13 | 19 |
| Race-Asian | 10 | 16 | 26 |
| Race-Black or African American | 2 | 4 | 6 |
| Race-Multiple | 5 | 2 | 7 |
| Race-Other | 2 | 1 | 3 |
| Race-Unknown or Not Reported | 3 | 5 | 8 |
| Race-White | 536 | 519 | 1055 |
Showing the first 100 of 279 sites across 31 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — We are committed to enhancing public health through responsible sharing of clinical trial data. Following approval of a new product or a new indication for an approved product in both the US and European Union, the study sponsor and/or its affiliated companies will share study protocols, anonymized patient data and study level data, and redacted clinical study reports with qualified scientific and medical researchers, upon request, as necessary for conducting legitimate research. Further information on how to request data can be found on our website bit.ly/IPD21
Supporting information: Study protocol, Statistical analysis plan, Clinical study report
Time frame: Within six months after the approval of a new product or a new indication for an approved product in both the United States and the European Union
Access criteria: Qualified scientific and medical researchers can request the data. Such requests must be submitted in writing to the company's portal and will be internally reviewed regarding criteria for researchers' qualification and legitimacy of the research proposal.
Data sharing details ↗ · bit.ly
Ran from Jun 2020 to primary completion in Oct 2023, 39 months.
Results were first posted in Jun 2025, 1 year 8 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Evobrutinib
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany →